Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - INJECTABLE;INJECTION - 100MG/5ML (20...DOSAGE - INJECTABLE;INJECTION - 100MG/5ML (20MG/ML)
USFDA APPLICATION NUMBER - 20571
DOSAGE - INJECTABLE;INJECTION - 300MG/15ML (2...DOSAGE - INJECTABLE;INJECTION - 300MG/15ML (20MG/ML)
USFDA APPLICATION NUMBER - 20571
DOSAGE - INJECTABLE;INJECTION - 40MG/2ML (20M...DOSAGE - INJECTABLE;INJECTION - 40MG/2ML (20MG/ML)
USFDA APPLICATION NUMBER - 20571
DOSAGE - INJECTABLE, LIPOSOMAL;INTRAVENOUS - ...DOSAGE - INJECTABLE, LIPOSOMAL;INTRAVENOUS - EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML)
USFDA APPLICATION NUMBER - 207793
Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Minbiotech
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kirsch Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]BioSpectra
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nippon Fine Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Zhejiang Huakang Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Parenteral
Film Formers & Plasticizers
Coating Systems & Additives
Fillers, Diluents & Binders
Taste Masking
Surfactant & Foaming Agents
Emulsifying Agents
Solubilizers
Topical
Co-Processed Excipients
Chewable & Orodispersible Aids
Thickeners and Stabilizers
Dry Powder Inhalation
Controlled & Modified Release
Soft Gelatin
Direct Compression
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
US Patents
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
96
PharmaCompass offers a list of Irinotecan Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Irinotecan Hydrochloride manufacturer or Irinotecan Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Irinotecan Hydrochloride manufacturer or Irinotecan Hydrochloride supplier.
A DQ-2805 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of DQ-2805, including repackagers and relabelers. The FDA regulates DQ-2805 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. DQ-2805 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of DQ-2805 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A DQ-2805 supplier is an individual or a company that provides DQ-2805 active pharmaceutical ingredient (API) or DQ-2805 finished formulations upon request. The DQ-2805 suppliers may include DQ-2805 API manufacturers, exporters, distributors and traders.
click here to find a list of DQ-2805 suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A DQ-2805 DMF (Drug Master File) is a document detailing the whole manufacturing process of DQ-2805 active pharmaceutical ingredient (API) in detail. Different forms of DQ-2805 DMFs exist exist since differing nations have different regulations, such as DQ-2805 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A DQ-2805 DMF submitted to regulatory agencies in the US is known as a USDMF. DQ-2805 USDMF includes data on DQ-2805's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The DQ-2805 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of DQ-2805 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The DQ-2805 Drug Master File in Japan (DQ-2805 JDMF) empowers DQ-2805 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the DQ-2805 JDMF during the approval evaluation for pharmaceutical products. At the time of DQ-2805 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of DQ-2805 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a DQ-2805 Drug Master File in Korea (DQ-2805 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of DQ-2805. The MFDS reviews the DQ-2805 KDMF as part of the drug registration process and uses the information provided in the DQ-2805 KDMF to evaluate the safety and efficacy of the drug.
After submitting a DQ-2805 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their DQ-2805 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of DQ-2805 suppliers with KDMF on PharmaCompass.
A DQ-2805 CEP of the European Pharmacopoeia monograph is often referred to as a DQ-2805 Certificate of Suitability (COS). The purpose of a DQ-2805 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of DQ-2805 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of DQ-2805 to their clients by showing that a DQ-2805 CEP has been issued for it. The manufacturer submits a DQ-2805 CEP (COS) as part of the market authorization procedure, and it takes on the role of a DQ-2805 CEP holder for the record. Additionally, the data presented in the DQ-2805 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the DQ-2805 DMF.
A DQ-2805 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. DQ-2805 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of DQ-2805 suppliers with CEP (COS) on PharmaCompass.
A DQ-2805 written confirmation (DQ-2805 WC) is an official document issued by a regulatory agency to a DQ-2805 manufacturer, verifying that the manufacturing facility of a DQ-2805 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting DQ-2805 APIs or DQ-2805 finished pharmaceutical products to another nation, regulatory agencies frequently require a DQ-2805 WC (written confirmation) as part of the regulatory process.
click here to find a list of DQ-2805 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing DQ-2805 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for DQ-2805 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture DQ-2805 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain DQ-2805 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a DQ-2805 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of DQ-2805 suppliers with NDC on PharmaCompass.
DQ-2805 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of DQ-2805 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right DQ-2805 GMP manufacturer or DQ-2805 GMP API supplier for your needs.
A DQ-2805 CoA (Certificate of Analysis) is a formal document that attests to DQ-2805's compliance with DQ-2805 specifications and serves as a tool for batch-level quality control.
DQ-2805 CoA mostly includes findings from lab analyses of a specific batch. For each DQ-2805 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
DQ-2805 may be tested according to a variety of international standards, such as European Pharmacopoeia (DQ-2805 EP), DQ-2805 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (DQ-2805 USP).
